Nabriva Therapeutics

Nabriva Therapeutics

Clinical stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections
Dublin Ireland (HQ), Vienna Austria, King of Prussia United States

Nabriva Therapeutics Company information

Edit
Date
Employees
104 people
Ownership
Market cap
$94m
Net debt
$46m
Firm valuation
€44m (Public information from 2020)
USD20162017201820192020E2021E2022E
Revenues-5m10m9m6m25m46m
% growth--100 %(10 %)(33 %)317 %84 %
EBITDA-(73m)(114m)(79m)(67m)(57m)-
% EBITDA margin-(1460 %)(1140 %)(878 %)(1117 %)(228 %)-
Profit-(74m)(115m)(82m)(62m)(45m)-
% profit margin-(1480 %)(1150 %)(911 %)(1033 %)(180 %)-
EV / Revenue--2.0x13.2x8.6x4.0x1.5x
EV / EBITDA---0.2x-1.6x-0.7x-1.8x-1.5x
  • Edit
DateInvestorsAmountRound
-N/A
€2.6mEARLY VC
€800kEARLY VC
€1.5mEARLY VC
$120mSERIES B
N/AN/AIPO
Total FundingFunding not available

Recent News about Nabriva Therapeutics

Edit
Lists
LocationEdit
25 North Wall Quay, North Dock, Dublin, Ireland

Investments by Nabriva Therapeutics

Edit
Are you an employee or an investor of this company?
Add your profile